Development of Immunopathogenesis Strategies to Treat Behçet’s Disease

Abstract

Behçet disease is a chronic relapsing vasculitis with unclear etiology and immunopathogenesis. Antigenic stimuli, antigen presenting cells, T cells, monocyte, and neutrophil and endothelial cells are major parts of the pathology of the disease. Understanding of the new pathogenic mechanisms based on molecular structure of the disease helps us in improving the novel therapeutic modalities. These drugs target specific and nonspecific inhibition of the immun system. These therapies include biologic agents, new topical and systemic immunosuppressants, tolerizing agents, and immunoablation. Novel treatment will be promising to treat the especially recalcitrant cases to conventional therapy. In this paper, new aspect of the immunopathogenesis of Behçet's diseases and novel treatment modalities will be discussed.

Thrombotic and Thromboembolic Complications in Systemic Vasculitis

“…Послед-няя, являясь результатом иммуновоспалительных из-менений в стенке сосудов, по-видимому, играет клю-чевую роль в патогенезе тромботических осложнений при болезни Бехчета. На повреждение эндотелиальных клеток указывает уменьшение концентрации оксида азота, повышение активности циркулирующего фак-тора фон Виллебранда и тромбомодулина, что осо-бенно заметно в активную стадию болезни [35]. У пациентов с болезнью Бехчета также повышена концентрация сосудистого эндотелиального фактора роста (маркера ангиогенеза) и молекул адгезии.…”

Cardiac pathology and modern therapeutic approach in Behçet disease

“…However, some authors [29,30] state that there is enough published experience to suggest that biotherapy may represent an important therapeutic improvement for patients with BD who have severe and resistant manifestations, or who are intolerant to standard immunosuppressive regimens. Considering the role of tumor necrosis factor (TNF)-a in triggering prothrombotic adhesion molecules, using TNF blocking agents in cardio-Behçet could be theoretically of some interest to reduce venous thrombosis relapse.…”

Behcet’s disease: a hardly diagnosed orphan disorder

“…Próbálkozás történt az IL-1β gátlására is, eddig kedvező eredmé-nyekkel. További lehetőség a Th17-asszociált citokinek blokkolása, de felmerült a hősokkfehérjékkel való toleranciakeltés lehetséges terápiás jelentősége is [48,49].…”